Disease Domain | Count |
---|---|
Neoplasms | 5 |
Hemic and Lymphatic Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Bispecific antibody | 4 |
Antibody | 1 |
Top 5 Target | Count |
---|---|
GPC3(Glypican-3) | 1 |
CD38 x PDL1 | 1 |
EGFR x HER3 | 1 |
Target |
Mechanism GPC3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EGFR antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
OT-A201 | Neoplasms More | Preclinical |
BMX-500 | Neoplasms More | Preclinical |
BMX-502 ( GPC3 ) | Neoplasms More | Preclinical |
BMX-003 ( EGFR x HER3 ) | Neoplasms More | Preclinical |
BMX-101 ( CD38 x PDL1 ) | Multiple Myeloma More | Preclinical |